AYTUAYTU BIOPHARMA, INC同业对比
AYTU BIOPHARMA, INC 与Pharmaceutical Preparations的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Pharmaceutical Preparations)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AYTU本股 | $25M#8 | — | 0.7x#1 | 0.4x#1 | 1.8%#4 | 14.4%#9 | -11.8%#1 | -38.6%#3 | -41.4%#3 | 4#2 | -1.7%#5 | — |
| ARTL | $30M#1 | — | 6.1x#12 | — | — | -31.1%#13 | — | -257.7%#12 | — | — | -97.1%#15 | — |
| HEPA | $29M#2 | — | 22.4x#15 | — | — | 37.3%#7 | — | -647.5%#14 | — | — | -17.6%#7 | — |
| TXMD | $26M#3 | — | 1.0x#4 | 8.6x#5 | 71.6%#1 | 73.9%#1 | -145.3%#3 | -2.1%#2 | -3.8%#1 | 5#1 | 99.1%#1 | — |
| NNVC | $26M#4 | — | 2.8x#8 | — | — | -14.1%#11 | — | -103.4%#8 | -89.9%#6 | — | -16.9%#6 | — |
| LTRN | $25M#5 | — | — | — | — | 17.6%#8 | — | — | — | — | -54.4%#11 | — |
| ATOS | $25M#6 | — | 0.9x#3 | 14191.3x#10 | -95.6%#9 | -36.3%#14 | -2112684.9%#10 | -129.6%#9 | — | — | -78.5%#13 | — |
| TVRD | $25M#7 | — | 3.0x#9 | 3.5x#3 | -66.0%#7 | 38.1%#6 | -374.8%#6 | -217.3%#11 | — | — | -93.4%#14 | — |
| PTN | $24M#9 | 121.9x#2 | 2.3x#7 | — | -100.0%#10 | -41.8%#15 | — | 163.3%#1 | -2281.5%#9 | — | — | — |
| CLRB | $23M#10 | — | 0.8x#2 | — | — | 51.1%#3 | — | -72.9%#5 | — | — | -49.9%#10 | — |
| ABVC | $23M#11 | — | 2.2x#6 | 76.8x#9 | 0.0%#5 | -61.3%#16 | -2416.0%#8 | -76.9%#6 | -68.5%#4 | — | -68.5%#12 | — |
| BFRI | $22M#12 | — | 3.8x#10 | 0.5x#2 | 11.7%#2 | 40.7%#5 | -27.2%#2 | -176.9%#10 | -712.4%#7 | — | 78.6%#2 | — |
| COCP | $22M#13 | — | 21.2x#14 | 11.0x#7 | -69.3%#8 | 49.5%#4 | -447.8%#7 | -845.9%#15 | -20.4%#2 | 3#3 | -19.6%#8 | — |
| ALLR | $22M#14 | 0.0x#1 | 6.2x#13 | 68.1x#8 | — | 54.2%#2 | -3939.1%#9 | -317.6%#13 | — | — | -25.1%#9 | — |
| CYCN | $21M#15 | — | 4.2x#11 | 10.2x#6 | 3.7%#3 | -15.4%#12 | -239.8%#4 | -69.4%#4 | -69.1%#5 | — | 70.3%#3 | — |
| MRKR | $21M#16 | — | 1.7x#5 | 5.9x#4 | -46.2%#6 | -13.3%#10 | -363.5%#5 | -100.0%#7 | -1413.6%#8 | — | 45.7%#4 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-03。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议